Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine

Pityriasis rosea‐like eruptions following vaccination with BNT162b2 mRNA COVID‐19 Vaccine

COVID-19 has caused cutaneous symptoms in approximately 20% of patients, ranging from inflammatory and exanthematous eruptions to vasculopathic and vasculitic lesions. Newly developed vaccines display high efficacy and low rates of adverse events. In the BNT162b2 (Pfizer/BioNTech) mRNA vaccine Phase...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of the European Academy of Dermatology and Venereology 2021-09, Vol.35 (9), p.e546-e548
Hauptverfasser: Cyrenne, B.M., Al‐Mohammedi, F., DeKoven, J.G., Alhusayen, R.
Format: Artikel
Sprache:eng
Schlagworte:
Covid‐19 Special Forum
Letter to the Editor
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:COVID-19 has caused cutaneous symptoms in approximately 20% of patients, ranging from inflammatory and exanthematous eruptions to vasculopathic and vasculitic lesions. Newly developed vaccines display high efficacy and low rates of adverse events. In the BNT162b2 (Pfizer/BioNTech) mRNA vaccine Phase III study, no participants reported cutaneous adverse events aside from injection site reactions. We report two cases of cutaneous eruptions following BNT162b2 vaccination for COVID-19.
ISSN:0926-9959
1468-3083
DOI:10.1111/jdv.17342